The impact of hypoxia on mustard vesicant-induced eye injury
Active Grant Awarded
- Award ID
- R01EY037652
- Recipient
-
Tufts Medical Center Parent, Inc. UEI MY2ERHGDV956
- Awarding agency
-
National Eye Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,496,120
Award facts
- Assistance listing
- 93.310 Trans-NIH Research Support
- Completion date 6% complete
- Funding agency
- Office of the Director National Institutes of Health, Department of Health and Human Services
- Place of performance
- Massachusetts, USA
Award details come from USAspending.gov.
About this award
The HHS National Institutes of Health Office of the Director awarded Tufts Medical Center Parent, Inc., doing business as Tufts Medical Center, a grant obligating $1.49612 million on September 17, 2026, under Trans-NIH Research Support (CFDA 93.310). The award funds research testing whether mustard vesicant exposure to the eye induces hypoxia and hypoxia-inducible factor (HIF) signaling that drives cellular damage, excessive inflammation, and pathological angiogenesis. The work uses human ocular tissues and animal models across three aims. Aim 1 measures intraocular oxygen levels and HIF activation after in vivo mustard exposure and determines HIF downstream signaling in human ocular tissues in vitro. Aim 2 assesses whether HIF activation induces mitochondrial dysfunction, metabolic reprogramming, and oxidative stress, modulating HIF with promoters and inhibitors and measuring effects on glycolysis, mitochondrial function, and reactive oxygen species production. Aim 3 treats mustard vesicant-exposed animals. The period of performance ends August 31, 2029, and work is performed in Massachusetts, USA.
Description
- Abstract
- Mustard vesicants, such as sulfur mustard and nitrogen mustard, are chemical weapons of mass destruction that can severely damage the eye. Acute exposure leads to corneal epithelial defects, corneal edema, conjunctival injection, eyelid swelling, and intraocular inflammation. Chronic disease is characterized by limbal ischemia, conjunctival vascular abnormalities, corneal scarring and neovascularization, and damage to the iris and retina. Despite numerous studies in humans and animals, the underlying mechanisms of mustard vesicant- induced eye injury remain unclear, and to date, there is no targeted treatment. Hypoxia (low oxygen levels) plays critical roles in mustard vesicant-induced skin and lung injuries and in non-vesicant ocular chemical burns, but its role in ocular mustard vesicant injury remains unknown. Hypoxia-inducible factors (HIFS) are master transcription factors that mediate cellular adaptation to hypoxia. We hypothesize that mustard vesicant exposure to the eye induces immediate and persistent hypoxia and HIF signaling, which promote cellular damage and lead to excessive inflammation and pathological angiogenesis. We will test this hypothesis using human tissues and animal models and employ a variety of cellular and molecular methods in three specific aims. In aim 1, we will determine intraocular oxygen levels and HIF activation after mustard exposure in vivo. We will determine HIF downstream signaling using human ocular tissues in vitro. In aim 2, we will assess whether HIF activation following mustard exposure induces mitochondrial dysfunction, metabolic reprogramming, and oxidative stress in ocular tissues. We will modulate HIF activation with promoters and inhibitors, and assess their effects on glycolysis, mitochondrial function, and the production of reactive oxygen species in ocular cells and tissues. In aim 3, we will treat mustard vesicant-exposed animals with topical oxygen therapy or HIF inhibitors. We will determine whether these therapies can mitigate eye injury by reducing excessive inflammation and pathological angiogenesis. We believe that hypoxia and HIF activation are not only acute responses to mustard injury but also initiate and propagate other pathophysiological processes, which in turn exacerbate and perpetuate tissue hypoxia beyond the acute stage, creating a vicious cycle of hypoxia and cellular/tissue damage. Successful completion of this proposal will not only fill knowledge gaps in chemical injury-related hypoxia research but also provide the first proof-of-concept data demonstrating the therapeutic potential of reversing tissue hypoxia or suppressing HIF signaling as novel topical medical countermeasures for mustard vesicant exposure.
Quick answers
Who received award R01EY037652?
R01EY037652 was awarded to Tufts Medical Center Parent, Inc. by National Eye Institute (National Institutes of Health) on September 17, 2026.
How much is award R01EY037652 worth?
$1,496,120 has been obligated on R01EY037652.
Which agency awarded R01EY037652?
National Eye Institute (National Institutes of Health) awarded R01EY037652, with funding from Office of the Director (National Institutes of Health).
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award